schizophrenia

[Scientific Reports] Researchers investigated the role of proprotein convertase subtilisin kexin type 9 (PCSK9) and explored the therapeutic effect of metformin for olanzapine-associated non-alcoholic fatty liver disease.

[npj Schizophrenia] The authors suggested that lncRNA RP5-998N21.4 was a critical regulator of immune defense, providing etiological and therapeutic implications for schizophrenia.

[Reviva Pharmaceuticals Holdings, Inc.] Reviva Pharmaceuticals Holdings, Inc. announced that the first patients have been dosed in a pivotal Phase III study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia.

[Stem Cell Reports] Investigators discussed available tools, including CRISPR-Cas9, and the applications of these tools to develop cell-based 2D models and 3D brain organoid models that better represent and unravel the intricacies of neuropsychiatric disorder pathophysiology.

[Nature Communications] Scientists integrated human genetics with transcriptomic data from differentiation of human ESCs into cortical excitatory neurons.

[Trends in Neurosciences] The authors highlight reproducible findings and emerging trends in recent schizophrenia-related iPSC studies and illuminate the relevance of the results in the context of human brain development.